Precision medicine for indolent systemic mastocytosis
Part of Cancer, Immune system & allergy clinical trials.
This study looks at a personalized approach to managing indolent systemic mastocytosis, a condition where too many mast cells build up in the body. The goal is to see if tailoring treatment based on individual characteristics can improve symptoms and quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a diagnosis of indolent systemic mastocytosis, as confirmed by your doctor.
- Your usual medications for mastocytosis have been at the same dose for at least 2 weeks before joining.
- You are generally able to take care of yourself (day-to-day tasks), even if you have some symptoms.
- You do not have advanced systemic mastocytosis, which is a more severe form of the disease.
- You have not had certain strong treatments (like cladribine, interferon, or antibody therapy) in the last 28 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks for a specific genetic change (KIT-D816V mutation) in the blood of adults with mast cell disorders—conditions where immune cells called mast cells cause allergic-like reactions. Understanding this mutation may help doctors better diagnose and treat your condition.
This registry collects information from people with mastocytosis (a condition where too many mast cells build up in the skin or organs) who are treated at a specific clinic in Italy. The goal is to better understand how the disease changes over time from childhood to adulthood.
This study is observing adults with indolent systemic mastocytosis (ISM) who are already receiving or planning to start symptom treatments or the drug avapritinib. It aims to learn more about how these treatments work in real life.
This study looks at how avapritinib works in people with indolent systemic mastocytosis whose symptoms are not well controlled by other treatments. You will take the drug as part of your usual care, and researchers will collect information to see how well it helps.
This trial tests BLU-263, a study medicine, against placebo (inactive treatment) to see if it improves symptoms in people with indolent systemic mastocytosis. It also checks safety and how well the dose is tolerated before and during treatment.
This program provides early access to bezuclastinib for people with systemic mastocytosis who are not getting enough help from current treatments and cannot join a clinical trial. It aims to offer a potential treatment option.
Hear when a new Systemic Mastocytosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.